These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 27707530)

  • 21. Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil.
    Citrome L
    Expert Rev Clin Pharmacol; 2016; 9(2):169-86. PubMed ID: 26573020
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: a case report.
    Eum S; Schneiderhan ME; Brown JT; Lee AM; Bishop JR
    BMC Psychiatry; 2017 Jul; 17(1):238. PubMed ID: 28673279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study.
    Kane JM; Sanchez R; Perry PP; Jin N; Johnson BR; Forbes RA; McQuade RD; Carson WH; Fleischhacker WW
    J Clin Psychiatry; 2012 May; 73(5):617-24. PubMed ID: 22697189
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia.
    McEvoy JP; Daniel DG; Carson WH; McQuade RD; Marcus RN
    J Psychiatr Res; 2007 Dec; 41(11):895-905. PubMed ID: 17631314
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early Placebo Improvement Is a Marker for Subsequent Placebo Response in Long-Acting Injectable Antipsychotic Trials for Schizophrenia: Combined Analysis of 4 RCTs.
    Kumagai F; Suzuki T; Fleischhacker WW; Yasui-Furukori N; Mimura M; Uchida H
    J Clin Psychiatry; 2018 Dec; 80(1):. PubMed ID: 30549487
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: A post hoc analysis of pooled data.
    Earley W; Guo H; Daniel D; Nasrallah H; Durgam S; Zhong Y; Patel M; Barabássy Á; Szatmári B; Németh G
    Schizophr Res; 2019 Feb; 204():282-288. PubMed ID: 30172595
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient-Centered Outcomes with Aripiprazole Once-Monthly for Maintenance Treatment in Patients with Schizophrenia: Results From Two Multicenter, Randomized, Double-Blind Studies.
    Kane JM; Sanchez R; Baker RA; Eramo A; Peters-Strickland T; Perry PP; Johnson BR; Tsai LF; Carson WH; McQuade RD; Fleischhacker WW
    Clin Schizophr Relat Psychoses; 2015; 9(2):79-87. PubMed ID: 25711509
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model.
    Hard ML; Mills RJ; Sadler BM; Wehr AY; Weiden PJ; von Moltke L
    CNS Drugs; 2017 Jul; 31(7):617-624. PubMed ID: 28597226
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intramuscular olanzapine versus intramuscular aripiprazole for the treatment of agitation in patients with schizophrenia: A pragmatic double-blind randomized trial.
    Kittipeerachon M; Chaichan W
    Schizophr Res; 2016 Oct; 176(2-3):231-238. PubMed ID: 27461399
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine].
    Raignoux C; Dusouchet T; Bret P; Queuille E; Biscay ML; Caron J; Bret MC
    Encephale; 2007 Dec; 33(6):973-81. PubMed ID: 18789790
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of paliperidone extended release in adolescents with schizophrenia: a randomized, double-blind study.
    Savitz AJ; Lane R; Nuamah I; Gopal S; Hough D
    J Am Acad Child Adolesc Psychiatry; 2015 Feb; 54(2):126-137.e1. PubMed ID: 25617253
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An Exploratory, Open-Label, Randomized Trial Comparing Risperidone Long-Acting Injectable with Oral Antipsychotic Medication in the Treatment of Early Psychosis.
    Malla A; Chue P; Jordan G; Stip E; Koczerginski D; Milliken H; Joseph A; Williams R; Adams B; Manchanda R; Oyewumi K; Roy MA
    Clin Schizophr Relat Psychoses; 2016; 9(4):198-208. PubMed ID: 23773886
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials.
    Glick ID; Mankoski R; Eudicone JM; Marcus RN; Tran QV; Assunção-Talbott S
    J Affect Disord; 2009 May; 115(1-2):18-26. PubMed ID: 19230981
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol.
    Andrezina R; Josiassen RC; Marcus RN; Oren DA; Manos G; Stock E; Carson WH; Iwamoto T
    Psychopharmacology (Berl); 2006 Oct; 188(3):281-92. PubMed ID: 16953381
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
    Li H; Rui Q; Ning X; Xu H; Gu N
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1002-8. PubMed ID: 21315787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study.
    Nasrallah HA; Silva R; Phillips D; Cucchiaro J; Hsu J; Xu J; Loebel A
    J Psychiatr Res; 2013 May; 47(5):670-7. PubMed ID: 23421963
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early antipsychotic response to aripiprazole in adolescents with schizophrenia: predictive value for clinical outcomes.
    Correll CU; Zhao J; Carson W; Marcus R; McQuade R; Forbes RA; Mankoski R
    J Am Acad Child Adolesc Psychiatry; 2013 Jul; 52(7):689-698.e3. PubMed ID: 23800482
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of a Schizophrenia Risk Variant at the DRD2 Locus With Antipsychotic Treatment Response in First-Episode Psychosis.
    Zhang JP; Robinson DG; Gallego JA; John M; Yu J; Addington J; Tohen M; Kane JM; Malhotra AK; Lencz T
    Schizophr Bull; 2015 Nov; 41(6):1248-55. PubMed ID: 26320194
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aripiprazole Lauroxil: A Review in Schizophrenia.
    Frampton JE
    Drugs; 2017 Dec; 77(18):2049-2056. PubMed ID: 29177572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.